

E This study aims to explore the potential of psilocybin in targeting relapse in opioid addiction. The research is designed to investigate the neurobiological mechanisms and psychological effects of psilocybin on individuals with a history of opioid use.

I The study involves a controlled trial where participants will be administered psilocybin under medical supervision. The primary goal is to assess the immediate and long-term effects on relapse rates and psychological well-being.

L The research is conducted in a clinical setting, ensuring safety and ethical standards. Participants will be monitored throughout the trial, and any adverse effects will be promptly addressed.

C

The study is a randomized, double-blind, placebo-controlled trial. Participants are randomly assigned to either the psilocybin group or the placebo group. The trial is conducted in a clinical setting with medical supervision.

L The study is a randomized, double-blind, placebo-controlled trial. Participants are randomly assigned to either the psilocybin group or the placebo group. The trial is conducted in a clinical setting with medical supervision.

S The study is a randomized, double-blind, placebo-controlled trial. Participants are randomly assigned to either the psilocybin group or the placebo group. The trial is conducted in a clinical setting with medical supervision.

The study is a randomized, double-blind, placebo-controlled trial. Participants are randomly assigned to either the psilocybin group or the placebo group. The trial is conducted in a clinical setting with medical supervision.

N The study is a randomized, double-blind, placebo-controlled trial. Participants are randomly assigned to either the psilocybin group or the placebo group. The trial is conducted in a clinical setting with medical supervision.